Keyphrases
Pancreatic Ductal Adenocarcinoma
100%
Surgical Outcomes
100%
Response Predictors
100%
Response-outcome
100%
Vasculitis
100%
Neoadjuvant Chemotherapy
100%
Perineural Invasion
100%
Carbohydrate Antigen 19-9 (CA19-9)
100%
Stereotactic Body Radiation Therapy
55%
Oncological Outcomes
22%
Curative Resection
22%
Inclusion Criteria
11%
Confidence Interval
11%
Hazard Ratio
11%
Natural Killer Cells
11%
RNA Sequencing (RNA-seq)
11%
Immune Response
11%
Progression-free Survival
11%
Multivariate Analysis
11%
No Significant Difference
11%
Cell Proliferation
11%
Overall Survival
11%
Median Overall Survival
11%
Clinical Data
11%
Pancreatic Cancer
11%
Cytotoxic T Cells
11%
Patient Characteristics
11%
Treatment Protocol
11%
Surgical Resection
11%
Neoadjuvant Therapy
11%
Chemotaxis
11%
Vascular Inflammation
11%
Vascular Structure
11%
Survival Outcomes
11%
Surgical Specimen
11%
Poor Survival
11%
Prognosticator
11%
Failure Pattern
11%
Pancreatic Adenocarcinoma
11%
Transcriptomic Changes
11%
Therapy Groups
11%
Resectability
11%
Immune Interactions
11%
Differential Gene Expression
11%
Curative Intent Treatment
11%
Modern Treatment
11%
Borderline Resectable
11%
Response to Neoadjuvant Therapy
11%
Clinical T3
11%
Enrichment Map
11%
Medicine and Dentistry
Neoadjuvant Chemotherapy
100%
Vasculitis
100%
Perineural Invasion
100%
Pancreas Adenocarcinoma
100%
CA19-9
100%
Stereotactic Body Radiation Therapy
55%
Pancreatic Ductal Adenocarcinoma
33%
Overall Survival
22%
Neoadjuvant Therapy
22%
Natural Killer Cell
11%
RNA Sequence
11%
Hazard Ratio
11%
Progression Free Survival
11%
Cell Proliferation
11%
Immune Response
11%
Cytotoxic T-Cell
11%
Patient Characteristics
11%
Pancreas Cancer
11%
Transcriptomics
11%
Chemotaxis
11%
Differential Gene Expression
11%
Multivariate Analysis
11%